eFFECTOR Therapeutics Accounts Payable

eFFECTOR Therapeutics (EFTR) currently reports a accounts payable of $120K as of March 2026. That compares with $37K in the prior-year period — up 227.7% year over year. Use the charts on this page to explore eFFECTOR Therapeutics's accounts payable history and peer comparisons.

eFFECTOR Therapeutics's accounts payable increased from $37K to $120K — a 227.7% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

eFFECTOR Therapeutics reported $120K in accounts payable as of March 2026. That compares with $37K in the prior-year period — up 227.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $120K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for eFFECTOR Therapeutics, and consider following EFTR for alerts when major investors trade the stock.

eFFECTOR Therapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $120K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EFTR with unrelated industries.